Claus-Christoph Steffens

1.7k total citations · 1 hit paper
18 papers, 1.1k citations indexed

About

Claus-Christoph Steffens is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Claus-Christoph Steffens has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Claus-Christoph Steffens's work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (9 papers) and Gastric Cancer Management and Outcomes (4 papers). Claus-Christoph Steffens is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (9 papers) and Gastric Cancer Management and Outcomes (4 papers). Claus-Christoph Steffens collaborates with scholars based in Germany, United States and Switzerland. Claus-Christoph Steffens's co-authors include Dirk Arnold, Thierry André, C. Schlichting, Roger von Moos, Richard Greil, Vicente Alonso-Orduña, Belguendouz Bendahmane, Eric Van Cutsem, Olivier Bouché and Stefan Kubicka and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Claus-Christoph Steffens

17 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

2012 829 citations Jaafar Bennouna, Javier Sastre et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claus-Christoph Steffens Germany	7	972	481	310	164	149	18	1.1k
Vicente Alonso-Orduña Spain	7	832 0.9×	402 0.8×	261 0.8×	140 0.9×	135 0.9×	23	1.0k
Joseph J. Schulz United States	6	1.3k 1.3×	533 1.1×	469 1.5×	148 0.9×	131 0.9×	8	1.5k
Joe McKendrick Australia	7	865 0.9×	420 0.9×	292 0.9×	176 1.1×	142 1.0×	9	1.1k
A. Misino Italy	11	755 0.8×	368 0.8×	221 0.7×	106 0.6×	134 0.9×	25	983
Seta Shahin United States	8	812 0.8×	319 0.7×	186 0.6×	145 0.9×	127 0.9×	13	948
G Paoletti Italy	13	781 0.8×	352 0.7×	232 0.7×	137 0.8×	95 0.6×	29	977
Belguendouz Bendahmane France	11	1.1k 1.1×	428 0.9×	295 1.0×	269 1.6×	266 1.8×	16	1.3k
Christian Lerchenmüller Germany	16	582 0.6×	417 0.9×	128 0.4×	195 1.2×	164 1.1×	49	890
R Castan France	4	829 0.9×	392 0.8×	288 0.9×	166 1.0×	140 0.9×	6	1.0k
Andrew Strickland Australia	12	891 0.9×	436 0.9×	210 0.7×	278 1.7×	170 1.1×	31	1.1k

Countries citing papers authored by Claus-Christoph Steffens

Since Specialization

Citations

This map shows the geographic impact of Claus-Christoph Steffens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus-Christoph Steffens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus-Christoph Steffens more than expected).

Fields of papers citing papers by Claus-Christoph Steffens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claus-Christoph Steffens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus-Christoph Steffens. The network helps show where Claus-Christoph Steffens may publish in the future.

Co-authorship network of co-authors of Claus-Christoph Steffens

This figure shows the co-authorship network connecting the top 25 collaborators of Claus-Christoph Steffens. A scholar is included among the top collaborators of Claus-Christoph Steffens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claus-Christoph Steffens. Claus-Christoph Steffens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Steffens, Claus-Christoph, et al.. (2019). Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line – Results from the prospective German TLK cohort study. Lung Cancer. 130. 216–225. 34 indexed citations

Dörfel, Steffen, et al.. (2017). Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study. Breast Cancer. 25(3). 275–283. 4 indexed citations

Quidde, Julia, Susanna Hegewisch‐Becker, Ullrich Graeven, et al.. (2016). Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. Annals of Oncology. 27(12). 2203–2209. 18 indexed citations

Quidde, Julia, Ullrich Graeven, C. Lerchenmueller, et al.. (2016). Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial. Annals of Oncology. 27. vi184–vi184.

Steffens, Claus-Christoph, et al.. (2015). Observational study of adjuvant therapy with capecitabine in colon cancer. Current Medical Research and Opinion. 31(4). 731–741. 3 indexed citations

Hegewisch‐Becker, Susanna, Ullrich Graeven, Christian Lerchenmüller, et al.. (2015). Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. The Lancet Oncology. 16(13). 1355–1369. 176 indexed citations

Müller, Volkmar, Stefan Fuxius, Claus-Christoph Steffens, et al.. (2014). Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study. Oncology Research and Treatment. 37(12). 748–755. 9 indexed citations

Hegewisch-Becker, S., Ullrich Graeven, Christian Lerchenmüller, et al.. (2014). Maintenance Strategy with Fluoropyrimidines (Fp) Plus Bevacizumab (Bev), Bev Alone or No Treatment, Following a 24-Week First-Line Induction with Fp, Oxaliplatin (Ox) and Bev for Patients with Metastatic Colorectal Cancer: Mature Data and Subgroup Analysis of the Aio Krk 0207 Phase III Study. Annals of Oncology. 25. iv167–iv167. 7 indexed citations

Quidde, Julia, Dirk Arnold, S. Hegewisch-Becker, et al.. (2014). Quality of Life (Qol) in Patients with Metastatic Colorectal Cancer (Mcrc) Receiving Maintenance Therapy After First-Line Inductive Treatment: a Qol Sub-Analysis of the Aio Krk 0207 Phase III Trial. Annals of Oncology. 25. iv177–iv177. 1 indexed citations

10.

Arnold, Dirk, Ullrich Graeven, Christian Lerchenmüller, et al.. (2014). Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).. Journal of Clinical Oncology. 32(15_suppl). 3503–3503. 21 indexed citations

11.

Greil, Richard, Roger von Moos, Jaafar Bennouna, et al.. (2013). Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study.. Journal of Clinical Oncology. 31(15_suppl). 3604–3604. 1 indexed citations

12.

Stein, Alexander, Djordje Atanackovic, Bert Hildebrandt, et al.. (2013). FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study.. Journal of Clinical Oncology. 31(4_suppl). 515–515. 1 indexed citations

13.

Bennouna, Jaafar, Javier Sastre, Dirk Arnold, et al.. (2012). Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology. 14(1). 29–37. 829 indexed citations breakdown →

14.

Bouché, Olivier, Claus-Christoph Steffens, Thierry André, et al.. (2012). Efficacy and Safety of Treatment with Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with BEV + CT: Age Subgroup Analysis From a Randomised Phase III Intergroup Study (ML18147). Annals of Oncology. 23. ix190–ix191. 4 indexed citations

15.

Hegewisch‐Becker, Susanna, Christian Lerchenmüller, Anja Welt, et al.. (2011). Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial.. Journal of Clinical Oncology. 29(15_suppl). 1044–1044. 4 indexed citations

16.

Moehler, Markus, E. Kettner, S. Hegewisch-Becker, et al.. (2009). Preliminary results of a multicenter phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer. Journal of Clinical Oncology. 27(15_suppl). e15502–e15502. 3 indexed citations

17.

Steinberg, F., et al.. (1989). Scanning electron microscopic studies on the vascular system of xenotransplanted tumours.. PubMed. 165(7). 503–4. 1 indexed citations

18.

Winkelmann, W., et al.. (1978). [Metatropic dwarfism. Different reversal of spine deformity in monozygotic twins (author's transl)].. PubMed. 116(5). 691–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact